The Role of Neudesin as a Novel Biomarker – in Iraqi Patients with Parkinson's Disease and Osteoporosis

Abstract

Neuron-derived neurotrophic factor [NENF], a human plasma neurotrophic factor, also increases neurotrophic activity in conjunction with Parkinson's disease-related proteins in Neudesin. Although Neudesin (neuron-derived neurotrophic secreted protein) is a member of the membrane-associated progesterone receptor (MAPR) protein subclass, it is not evolutionary related to the other members of the same family. The expression of Neudesin is found in both brain and spinal cord from embryonic stages to adulthood, as w Neudesin levels in Parkinson's patients with osteoporosis disease and Parkinson's patients without osteoporosis disease, as well as the relationship between Neudesin levels, Anthropometric and Clinical Features (Age, Gender, BMI) and Serum Parathyroid Hormones vit D3, Ca and phosphorous, were studied in this study. Eighty individuals participated in this study. Osteoporosis is a risk factor for Parkinson's, and Osteoporosis is a risk factor for Parkinson's disease. In order to conduct this study, we selected patients from the Parkinson's Disease and Osteoporosis Center in Baghdad/ Alrisafa. G1 and G2 were (55-67) years old, (38-75) years old, and (55-66) years old, respectively. In all of the groups examined, the ratio of males to females has risen. Men are more likely than women to be diagnosed with Parkinson's disease, accounting for this disparity. Neudesin concentrations in G1 and G3 were substantially lower than those in G2 (P= ±0.0001), although G1's concentration was somewhat higher than G2's (0.803±0.091 ng./ml). A "cut-off value" for determining sensitivity and specificity to diagnose the condition was also determined in the study, which included examining the link between blood Neudesin levels and the classification of participants into cases and controls.